Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs

Advanced Drug Delivery Reviews

Volumn 62, Issue 4-5, 2010, Pages 491-502

  Sharma, Puneet ^a   Garg, Sanjay ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Dendrimer; HIV; Nanocrystal; Nanoparticle; Polymer; Polymeric micelle

Indexed keywords

ANTI-HIV; ANTIRETROVIRAL DRUGS; CLINICAL DEVELOPMENT; DEVELOPED COUNTRIES; DRUG DELIVERY SYSTEM; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HIV; HUMAN IMMUNODEFICIENCY VIRUS; IMPROVED SOLUBILITY; NANO-SCALE SYSTEM; POLYMER BASED; POLYMERIC MICELLE; WATER SOLUBILITIES;

BIOCHEMISTRY; DENDRIMERS; DEVELOPING COUNTRIES; DRUG DELIVERY; MICELLES; NANOPARTICLES; NANOTECHNOLOGY; SOLUBILITY; SYSTEM STABILITY; TERNARY SYSTEMS; VIRUSES;

NANOCRYSTALS;

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; APOLIPOPROTEIN E; APREPITANT; ATAZANAVIR; DARUNAVIR; DENDRIMER; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FENOFIBRATE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOVIRIDE; MARAVIROC; MEGESTROL ACETATE; NANOCRYSTAL; NANOPARTICLE; NELFINAVIR; POLOXAMER; POLYMER; PROTEINASE INHIBITOR; RALTEGRAVIR; RAPAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA; STAVUDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; BIOCOMPATIBILITY; DEGRADATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; HYDROPHOBICITY; IONIZATION; LIPID METABOLISM; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THERMODYNAMICS; VIRUS LOAD; X RAY DIFFRACTION;

ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; DENDRIMERS; DEVELOPING COUNTRIES; DRUG STABILITY; HUMANS; MICELLES; NANOTECHNOLOGY; POLYMERS; SOLUBILITY;

EID: 76849108225     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.019     Document Type: Review

References (110)

1. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33 (2009) 307-320
2. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., and Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 323 (2009) 1304-1307
3. Flexner C. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6 (2007) 959-966
4. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
5. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M.L., Lee V.H.L., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19 (2002) 921-925
6. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
7. Kasim N.A., Whitehouse M., Ramachandran C., Bermejo M., Lennernäs H., Hussain A.S., Junginger H.E., Stavchansky S.A., Midha K.K., Shah V.P., and Amidon G.L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharmacol. 1 (2004) 85-96
8. Williams G.C., and Sinko P.J. Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. 39 (1999) 211-238
9. Alexaki A., Liu Y., and Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Educ. Res. 6 (2008) 388-400
10. Varatharajan L., and Thomas S.A. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antivir. Res. 82 2 (2009) A99-A109
11. Chiappetta D.A., and Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 66 (2007) 303-317
12. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
13. Lee C.C., MacKay J.A., Fréchet J.M.J., and Szoka F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 23 (2005) 1517-1526
14. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 73 (2001) 137-172
15. Torchilin V.P. Block copolymer micelles as a solution for drug delivery problems. Expert Opin. Ther. Pat. 15 (2005) 63-75
16. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24 (2007) 1-16
17. Torchilin V.P., and Weissig V. Polymeric micelles for the delivery of poorly soluble drugs. ACS Symp. Ser. 752 (2000) 297-313
18. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
19. Galli C. Experimental determination of the diffusion boundary layer width of micron and submicron particles. Int. J. Pharm. 313 (2006) 114-122
20. Van Eerdenbrugh B., Froyen L., Martens J.A., Blaton N., Augustijns P., Brewster M., and Van den Mooter G. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm. 338 (2007) 198-206
21. Fakes M.G., Vakkalagadda B.J., Qian F., Desikan S., Gandhi R.B., Lai C., Hsieh A., Franchini M.K., Toale H., and Brown J. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int. J. Pharm. 370 (2009) 167-174
22. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., and Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285 (2004) 135-146
23. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
24. Constantinides P.P., Chaubal M.V., and Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60 (2008) 757-767
25. Dou H., Morehead J., Destache C.J., Kingsley J.D., Shlyakhtenko L., Zhou Y., Chaubal M., Werling J., Kipp J., Rabinow B.E., and Gendelman H.E. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358 (2007) 148-158
26. Baert L., van 't Klooster G., Dries W., Francois M., Wouters A., Basstanie E., Iterbeke K., Stappers F., Stevens P., Schueller L., Van Remoortere P., Kraus G., Wigerinck P., and Rosier J. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72 3 (2009) 502-508
27. G.G. Liversidge, K.C. Cundy, J.F. Bishop, D.A. Czekai, Surface modified drug nanoparticles, United States Patent 5, 145, 6841992.
28. Bottomley K. Nanotechnology for drug delivery: a validated technology?. Drug Delivery Report Autumn/Winter (2006) 20-21
29. Martin A., Bustamante P., and Chun A.H.C. Interfacial phenomenon. Physical Pharmacy (1993), Lippincott Williams & Wilkins, Maryland 362-392
30. Adams M.L., Lavasanifar A., and Kwon G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 92 (2003) 1343-1355
31. Adams M.L., Lavasanifar A., and Kwon G.S. Erratum: amphiphilic block copolymers for drug delivery. (Journal of Pharmaceutical Research (2003) 92, 7 (1343-1355) doi:10.1002/jps.10397). J. Pharm. Sci. 94 (2005) 1160
32. Bromberg L. Polymeric micelles in oral chemotherapy. J. Control. Release 128 (2008) 99-112
33. Nagasaki Y., Yasugi K., Yamamoto Y., Harada A., and Kataoka K. Sugar-installed block copolymer micelles: their preparation and specific interaction with lectin molecules. Biomacromolecules 2 (2001) 1067-1070
34. Allen C., Maysinger D., and Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf., B. Biointerfaces 16 (1999) 3-27
35. Aliabadi H.M., Shahin M., Brocks D.R., and Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin. Pharmacokinet. 47 (2008) 619-634
36. Shaik N., Pan G., and Elmquist W.F. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J. Pharm. Sci. 97 (2008) 5421-5433
37. Batrakova E.V., Li S., Miller D.W., and Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16 (1999) 1366-1372
38. Batrakova E.V., Miller D.W., Li S., Alakhov V.Y., Kabanov A.V., and Elmquist W.F. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296 (2001) 551-557
39. Miller D.W., Batrakova E.V., and Kabanov A.V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm. Res. 16 (1999) 396-401
40. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
41. Lledo-Garcia R., Nacher A., Prats-Garcia L., Casabo V.G., and Merino-Sanjuan M. Bioavailability and pharmacokinetic model for ritonavir in the rat. J. Pharm. Sci. 96 (2007) 633-643
42. Richter M., Gyemant N., Molnar J., and Hilgeroth A. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors. Pharm. Res. 21 (2004) 1862-1866
43. Tong L., Phan T.K., Robinson K.L., Babusis D., Strab R., Bhoopathy S., Hidalgo I.J., Rhodes G.R., and Ray A.S. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51 (2007) 3498-3504
44. Usansky H.H., Hu P., and Sinko P.J. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. Drug Metab. Dispos. 36 (2008) 863-869
45. Huisman M.T., Smit J.W., Wiltshire H.R., Hoetelmans R.M.W., Beijnen J.H., and Schinkel A.H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59 (2001) 806-813
46. Zastre J.A., Chan G.N.Y., Ronaldson P.T., Ramaswamy M., Couraud P.O., Romero I.A., Weksler B., Bendayan M., and Bendayan R. Up-regulation of p-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87 (2009) 1023-1036
47. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., and Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16 (1999) 1206-1212
48. Johnson M., Grinsztejn B., Rodriguez C., Coco J., DeJesus E., Lazzarin A., Lichtenstein K., Rightmire A., Sankoh S., and Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19 (2005) 685-694
49. Perloff E.S., Duan S.X., Skolnik P.R., Greenblatt D.J., and Von Moltke L.L. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33 (2005) 764-770
50. Ribera E., Azuaje C., Lopez R.M., Diaz M., Feijoo M., Pou L., Crespo M., Curran A., Ocana I., and Pahissa A. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 20 (2006) 1131-1139
51. Young B., Fischl M.A., Wilson H.M., Finn T.S., Jensen E.H., DiNubile M.J., and Zeldin R.K. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J. Acquir. Immune Defic. Syndr. 31 (2002) 478-482
52. Sosnik A., Chiappetta D.A., and Carcaboso A.M. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J. Control. Release 138 1 (2009) 2-15
53. Alakhov V.Y., Moskaleva E.Y., Batrakova E.V., and Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem. 7 (1996) 209-216
54. Batrakova E.V., Han H.Y., Alakhov V.Y., Miller D.W., and Kabanov A.V. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15 (1998) 850-855
55. Spitzenberger T.J., Heilman D., Diekmann C., Batrakova E.V., Kabanov A.V., Gendelman H.E., Elmquist W.F., and Persidsky Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J. Cereb. Blood Flow Metab. 27 (2007) 1033-1042
56. Batrakova E.V., and Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 130 (2008) 98-106
57. Kuo Y.C., and Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 327 (2006) 160-169
58. Kuo Y.C., and Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 351 (2008) 271-281
59. Lobenberg R., Araujo L., Von Briesen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 (1998) 21-30
60. Lobenberg R., and Kreuter J. Macrophage targeting of azidothymidine: a promising strategy for AIDS therapy. AIDS Res. Hum. Retrovir. 12 (1996) 1709-1715
61. Zensi A., Begley D., Pontikis C., Legros C., Mihoreanu L., Wagner S., Buchel C., von Briesen H., and Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137 1 (2009) 78-86
62. Govender T., Ojewole E., Naidoo P., and Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 15 (2008) 493-501
63. Ojewole E., Mackraj I., Naidoo P., and Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur. J. Pharm. Biopharm. 70 (2008) 697-710
64. Schafer V., Von Briesen H., Andreesen R., Steffan A.M., Royer C., Troster S., Kreuter J., and Rubsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9 (1992) 541-546
65. Shah L.K., and Amiji M.M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23 (2006) 2638-2645
66. Giri M.S., Nebozyhn M., Raymond A., Gekonge B., Hancock A., Creer S., Nicols C., Yousef M., Foulkes A.S., Mounzer K., Shull J., Silvestri G., Kostman J., Collman R.G., Showe L., and Montaner L.J. Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J. Immunol. 182 (2009) 4459-4470
67. Orenstein J.M. The macrophage in HIV infection. Immunobiology 204 (2001) 598-602
68. Weiss R.A. How does HIV cause AIDS?. Science 260 (1993) 1273-1279
69. Orenstein J.M., Fox C., and Wahl S.M. Macrophages as a source of HIV during opportunistic infections. Science 276 (1997) 1857-1860
70. Chellat F., Merhi Y., Moreau A., and Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 26 (2005) 7260-7275
71. Leu D., Manthey B., and Kreuter J. Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. J. Pharm. Sci. 73 (1984) 1433-1437
72. Pierige F., Serafini S., Rossi L., and Magnani M. Cell-based drug delivery. Adv. Drug Deliv. Rev. 60 (2008) 286-295
73. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
74. Storm G., Belliot S.O., Daemen T., and Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17 (1995) 31-48
75. Owens III D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 (2006) 93-102
76. Vonarbourg A., Passirani C., Saulnier P., and Benoit J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27 (2006) 4356-4373
77. Ham A.S., Cost M.R., Sassi A.B., Dezzutti C.S., and Rohan L.C. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 26 (2009) 502-511
78. Woodrow K.A., Cu Y., Booth C.J., Saucier-Sawyer J.K., Wood M.J., and Mark Saltzman W. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 8 (2009) 526-533
79. Desai M.P., Labhasetwar V., Amidon G.L., and Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13 (1996) 1838-1845
80. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., and Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1482-1487
81. Cu Y., and Saltzman W.M. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharmacol. 6 (2009) 173-181
82. Chiappetta D.A., Carcaboso A.M., Bregni C., Rubio M., Bramuglia G., and Sosnik A. Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 10 (2009) 1-6
83. Villalonga-Barber C., Micha-Screttas M., Steele B.R., Georgopolous A., and Demetzos C. Dendrimers as biopharmaceuticals: synthesis and properties. Curr. Top. Med. Chem. 8 (2008) 1294-1309
84. El-Sayed M., Ginski M., Rhodes C., and Ghandehari H. Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J. Control. Release 81 (2002) 355-365
85. El-Sayed M., Ginski M., Rhodes C.A., and Ghandehari H. Influence of surface chemistry of poly(amidoamine) dendrimers on Caco-2 cell monolayers. J. Bioact. Compat. Polym. 18 (2003) 7-22
86. El-Sayed M., Rhodes C.A., Ginski M., and Ghandehari H. Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int. J. Pharm. 265 (2003) 151-157
87. Jevprasesphant R., Penny J., Jalal R., Attwood D., McKeown N.B., and D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252 (2003) 263-266
88. Kitchens K.M., Foraker A.B., Kolhatkar R.B., Swaan P.W., and Ghandehari H. Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 24 (2007) 2138-2145
89. Kitchens K.M., Kolhatkar R.B., Swaan P.W., Eddington N.D., and Ghandehari H. Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling. Pharm. Res. 23 (2006) 2818-2826
90. Pisal D.S., Yellepeddi V.K., Kumar A., Kaushik R.S., Hildreth M.B., Guan X., and Palakurthi S. Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. Int. J. Pharm. 350 (2008) 113-121
91. Kitchens K.M., El-Sayed M.E.H., and Ghandehari H. Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv. Drug Deliv. Rev. 57 (2005) 2163-2176
92. D'Emanuele A., Jevprasesphant R., Penny J., and Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control. Release 95 (2004) 447-453
93. Wiwattanapatapee R., Carreno-Gomez B., Malik N., and Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system?. Pharm. Res. 17 (2000) 991-998
94. Aillon K.L., Xie Y., El-Gendy N., Berkland C.J., and Forrest M.L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Deliv. Rev. 61 (2009) 457-466
95. Jevprasesphant R., Penny J., Attwood D., McKeown N.B., and D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 20 (2003) 1543-1550
96. Kolhatkar R.B., Kitchens K.M., Swaan P.W., and Ghandehari H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug. Chem. 18 (2007) 2054-2060
97. Neerman M.F., Zhang W., Parrish A.R., and Simanek E.E. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int. J. Pharm. 281 (2004) 129-132
98. Chen H.T., Neerman M.F., Parrish A.R., and Simanek E.E. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 126 (2004) 10044-10048
99. Whelan J. First clinical data on RNAi. Drug Discov. Today 10 (2005) 1014-1015
100. Keller M. Nanomedicinal delivery approaches for therapeutic siRNA. Int. J. Pharm. 379 2 (2009) 210-211
101. Capodici J., Karikó K., and Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J. Immunol. 169 (2002) 5196-5201
102. Hu W.Y., Myers C.P., Kilzer J.M., Pfaff S.L., and Bushman F.D. Inhibition of retroviral pathogenesis by RNA interference. Curr. Biol. 12 (2002) 1301-1311
103. Jacque J.M., Triques K., and Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 418 (2002) 435-438
104. Mao S., Neu M., Germershaus O., Merkel O., Sitterberg J., Bakowsky U., and Kissel T. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug. Chem. 17 (2006) 1209-1218
105. Weber N., Ortega P., Clemente M.I., Shcharbin D., Bryszewska M., de la Mata F.J., Gómez R., and Muñoz-Fernández M.A. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control. Release 132 (2008) 55-64
106. Dutta T., Garg M., and Jain N.K. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci. 34 (2008) 181-189
107. Dutta T., and Jain N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta, Gen. Subj. 1770 (2007) 681-686
108. Cui Z., Hsu C.H., and Mumper R.J. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev. Ind. Pharm. 29 (2003) 689-700
109. Margolis L., and Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat. Rev. Microbiol. 4 (2006) 312-317
110. Klasse P.J., Shattock R., and Moore J.P. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 59 (2008) 455-471